NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · IEX Real-Time Price · USD
2.000
-0.020 (-0.99%)
Jul 19, 2024, 4:00 PM EDT - Market closed
NovaBay Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for NBY.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for NBY.
Recommendation Trends
| Rating | Jan '22 | Feb '22 | Mar '22 | Apr '22 | May '22 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $5,206 → $4,900 | Strong Buy | Maintains | $5,206 → $4,900 | +244,900.00% | May 20, 2022 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2018 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $68,906 | Strong Buy | Initiates | $68,906 | +3,445,212.50% | Mar 6, 2013 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $68,906 | Strong Buy | Initiates | $68,906 | +3,445,212.50% | Mar 5, 2013 |
Financial Forecast
Revenue This Year
13.74M
from 14.73M
Decreased by -6.71%
Revenue Next Year
18.91M
from 13.74M
Increased by 37.62%
EPS This Year
-6.01
from -138.60
EPS Next Year
-0.35
from -6.01
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 15.3M | 21.5M |
| Avg | 13.7M | 18.9M |
| Low | 12.3M | 16.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 4.1% | 56.2% |
| Avg | -6.7% | 37.6% |
| Low | -16.1% | 21.3% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -5.51 | - |
| Avg | -6.01 | -0.35 |
| Low | -6.52 | -0.69 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.